News - Pharmaceutical, Asia-Pacific, Bristol-Myers Squibb

Bristol-Myers Squibb extends distribution in six Asian markets

Bristol-Myers Squibb extends distribution in six Asian markets


US drug major Bristol-Myers Squibb has extended its relationship with DKSH, a market expansion services…

Asia-PacificBristol-Myers SquibbMarkets & MarketingPharmaceutical

Amount of foreign direct investment proves India’s attraction to Big Pharma despite protestations on IP

Amount of foreign direct investment proves India’s attraction to Big Pharma despite protestations on IP


Multinational drugmakers might be crying themselves hoarse that India does not protect innovation - that…

Asia-PacificBristol-Myers SquibbFinancialGlaxoSmithKlineIndiaMerck & CoMergers & AcquisitionsMylan LaboratoriesPatentsPharmaceuticalSanofi

Ono Pharma files for approval of nivolumab for melanoma in Japan


Japanese drugmaker Ono Pharmaceutical has filed an application to obtain a manufacturing and marketing…

Asia-PacificBristol-Myers SquibbnivolumabOncologyOno PharmaceuticalPharmaceuticalRegulation

Novel oral anticoagulants will continue to drive atrial fibrillation drug market growth


The atrial fibrillation drug market will experience continued growth through the rest of the decade,…

Asia-PacificBayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularEliquisEuropeMarkets & MarketingNorth AmericaPfizerPharmaceuticalPradaxaXarelto

Bristol-Myers files for Japanese approval of first all-oral, interferon/ribavirin-free hep C treatment

Bristol-Myers files for Japanese approval of first all-oral, interferon/ribavirin-free hep C treatment


US drug major Bristol-Myers Squibb has filed a New Drug Application with Japan’s Pharmaceutical and…

Anti-viralsAsia-PacificasunaprevirBristol-Myers SquibbdaclatasvirPharmaceuticalRegulation

Growth drivers for China's type 2 diabetes market


The type 2 diabetes therapeutic market in China, the third largest after the USA and Japan, will grow…

Asia-PacificAstraZenecaBristol-Myers SquibbByettaDiabetesGalvusJanuviaMarkets & MarketingMerck & CoNovartisNovo NordiskOnglyzaPharmaceuticalVictoza

Bristol-Myers partners with South Korean firm on biopharma production


US pharma major Bristol-Myers Squibb (NYSE: BMY) has entered into a 10-year agreement under which Samsung…

Asia-PacificBiotechnologyBristol-Myers SquibbOncologyPharmaceuticalProductionSamsung BioLogics

Bristol-Myers and Simcere agree to co-develop/commercialize Orencia SC in China


US pharma major Bristol-Myers Squibb (NYSE: BMY) and China-based Simcere Pharmaceutical (NYSE: SCR) have…

Anti-Arthritics/RheumaticsAsia-PacificBiotechnologyBristol-Myers SquibbLicensingOrenciaPharmaceuticalSimcere Pharmaceutical

CML drug revenue in Japan to grow, despite global decline, says GlobalData


Bucking a global trend of falling revenues, weak penetration of generic drugs and an increasing patient…

Asia-PacificBristol-Myers SquibbGleevecMarkets & MarketingNovartisOncologyPatentsPharmaceuticalSprycel

Merck KGaA links with Bristol-Myers for Glucophage promotion in China


German drugs and chemicals group Merck KGaA this morning announced a collaboration with US pharma major…

Asia-PacificBristol-Myers SquibbDiabetesGlucophageGlucophage XRLicensingMarkets & MarketingMerck KGaAPharmaceutical

Indian govt plans compulsory licences for trastuzumab, ixabepilone and dasatinib


The Indian government's move to issue compulsory licences to three more patented cancer drugs has left…

Asia-PacificAvastinBristol-Myers SquibbGenericsIxempraOncologyPatentsPharmaceuticalRocheSprycel

Japanese approvals for Novo's Ryzodeg, UCB/Otsuka's Neupro and B-MS/Pfizer's Eliquis


Danish insulin giant Novo Nordisk (NOVN: NV) revealed on December 15 that the Japanese Ministry of Health,…

Asia-PacificBristol-Myers SquibbCardio-vascularDiabetesEliquisNeuproNeurologicalNovo NordiskOtsukaPfizerPharmaceuticalRegulationRyzodegUCB

Otsuka sells on Japanese saxagliptin rights to Kyowa Hakko


Japanese drugmakers Otsuka Pharmaceutical (TYO: 4578) and Kyowa Hakko Kirin (TYO: 4151) have entered…

Asia-PacificBristol-Myers SquibbDiabetesKyowa Hakko KirinLicensingOncologyOtsukaPharmaceuticalResearchsaxagliptin

Approval of diabetes drugs from AstraZeneca/B-MS and Novo Nordisk supported by EU’s CHMP; Faslodex cleared in Japan


The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued…

Asia-PacificAstraZenecaBristol-Myers SquibbDiabetesEuropeFaslodexKomboglyzeLevemirNovo NordiskOncologyPharmaceuticalRegulationsaxagliptinVictoza

Bristol-Myers gets more rights to Ono antibody in exchange for Japan co-rights to Orencia


US drug major Bristol-Myers Squibb (NYSE:BMY) says it has agreed with Japan’s Ono Pharmaceutical…

Anti-Arthritics/RheumaticsAsia-PacificBristol-Myers SquibbLicensingMarkets & MarketingOncologyOno PharmaceuticalOrenciaPharmaceutical

Back to top